
Barn owl nest box project aims to protect padi fields from rat menace
Handle with care: Hasber (right) demonstrating to Abdul Aziz how to hold barn owls correctly, with a nest box seen in the background. — ZHAFARAN NASIB/The Star
KEPALA BATAS: Every padi planting season, farmer Abdul Aziz Hashim endures sleepless nights worrying about the crops on his 2ha padi field.
Besides the unpredictable weather, thousands of rats have been destroying his crop, slashing his income by nearly 50%.
"These rats usually come out at night and feast on the matured padi. It gets worse during harvest time.
"I have tried using pesticides and rat poison to try to eliminate the pests.
"I spend thousands of ringgit each planting season just to protect my crops," the 43-year-old lamented.
However, Abdul Aziz, who has been a farmer for about 20 years, now realises that the use of chemicals is harmful to the environment and health.
"Pesticides do not only contaminate the padi fields but also pollute the surroundings and kill other animals," he said.
Farmers like Abdul Aziz are now relieved that they can now consider a more friendly form of rat control: using Eastern barn owls to hunt the rats.
Native to Peninsular Malaysia, the Eastern barn owl's voracious appetite for rats helps protect crops.
This pilot project by Universiti Sains Malaysia's (USM) Barn Owl and Rodent Research Group (BORG) will see 20 barn owl nest boxes installed at fields belonging to farmers under the B40 group in Paya Keladi, Kepala Batas.
The nest boxes are designed to attract owls to nest in them without additional human intervention, with Abdul Aziz saying the new method will help manage the rodent population effectively.
"It will reduce the need for chemical poisons," he explained.
"Although the use of barn owls was practised in the past by local farmers, there was little to no monitoring of rodent problems in the fields, which made it harder for farmers to protect their crops."
USM's Assoc Prof Dr Hasber Salim said his team initiated the project to help farmers adopt environmentally friendly practices.
"Rat damage can reduce yields by up to 60%. With barn owls present, farmers experience less crop loss, which translates to higher income and better quality harvests as one barn owl family can hunt up to 3,000 rats per year,' he said.
Under this pilot project carried out in collaboration with Malaysia's national rice agency Padiberas Nasional Bhd (Bernas), each nest box can serve an area of about 5ha to 10ha.
Each nest setup costs about RM800, depending on location and logistics, with funding made possible through a RM42,671 (US$10,000) grant from GlobalGiving, a US-based non-governmental organisation.
The project will be monitored over a period of three years.
Each week, BORG members will collect owl pellets – regurgitated remains of prey – to identify the species of rats consumed and estimate the number of pests removed.
'We will analyse the pellets to get actual data.
'That's how we estimate that a single owl family can eat up to 3,000 rats a year,' he said.
Hasber added that the initiative draws on past experience of using barn owls in oil palm plantations under a similar conservation project with the Malaysian Palm Oil Green Conservation Foundation.
"Although barn owls have been used in padi fields since the 1970s, the practice has been largely neglected in recent years.
'We're bringing back a proven concept but with improved planning and monitoring,' he said.
Hasber added that instead of using the outdated density of one nest per 40ha, his team is now using a high-density model of one nest per five to 10ha.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
2 hours ago
- Malaysian Reserve
Elon Musk's Neuralink closes Series E funding round
SAN FRANCISCO — Elon Musk's (picture) brain computer interface startup Neuralink announced on Monday that it has closed a US$650 million funding round, Xinhua reported. The Series E fundraiser included investors such as ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital, among others, the company said in a blog post. Neuralink last raised a US$280 million Series D funding round in 2023, with an additional US$43 million tranche added months later. The company said it has now conducted more human clinical trials, implanting its brain chips in five individuals with severe paralysis. In May, Neuralink received a Breakthrough Devices Programme designation from the US Food and Drug Administration (FDA). The Breakthrough Devices Programme is a voluntary programme for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, according to the FDA. The programme is intended to provide patients and healthcare providers with timely access to medical devices by speeding up development, assessment, and review for premarket approval. — BERNAMA-XINHUA


The Star
2 days ago
- The Star
Vietnam celebrates groundbreaking of US$300mil tech hub in Hanoi
Vietnam PM Pham Minh Chinh (centre) and delegates at the groundbreaking ceremony -- Photo: VNA HANOI (Vietnam News/ANN): Prime Minister Pham Minh Chinh on June 1 attended the groundbreaking ceremony for the Hanoi CMC Creative Space (CCS Hanoi), a US$300 million technology complex hailed as a key part of Vietnam's push for innovation and digital transformation. The project, led by private firm CMC Technology & Solution, located on an 11,000 sq.m site in Hanoi, will feature 23 floors above ground and three basements, with a total floor space exceeding 90,000 sq.m. Following the success of CMC's first creative space in Ho Chi Minh City - CCS Tan Thuan, this second facility will serve as an open artificial intelligence centre, dubbed It aims to house a comprehensive tech ecosystem, including a state-of-the-art data centre, research and development labs, training facilities, and a startup incubation zone, employing over 5,000 engineers. At the heart of the complex is the CMC Data Centre, designed to deploy cutting-edge technologies in artificial intelligence, cloud computing, cybersecurity, big data, and next-generation networks. The ecosystem will also integrate 25 core technologies developed by CMC. In his address, PM Chinh praised the project as a testament to the private sector's role in advancing Vietnam's technological ambitions, aligning with the Party's policy of making breakthroughs in sci-tech, innovation, and digital transformation. With Vietnam targeting at least 8% economic growth in 2025 and double-digit expansion thereafter, he called for national unity to drive prosperity, safeguard its independence, sovereignty, and territorial integrity. He urged CMC to lead in sci-tech, innovation and digital transformation, inspiring other businesses, educational establishments, and research centres, particularly young people, to contribute to Vietnam's rapid and sustainable development. He expressed his hope that CMC would grow into a major multinational corporation integrated into global value chains while prioritising social welfare and equitable access to technology, especially for remote and vulnerable communities. The Government will always accompany companies, including CMC, and request ministries, agencies, and Hanoi authorities to further support them by promptly removing any obstacles to their growth, he concluded. - Vietnam News/ANN


Malaysian Reserve
3 days ago
- Malaysian Reserve
Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR
DELRAY BEACH, Fla., May 30, 2025 /PRNewswire/ — The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine. The rising number of cancer cases worldwide and increased funding for various types of research are other important factors propelling the market's growth. Moreover, advances in omics technologies, including genomics and proteomics, are now enabling the development of more sophisticated tests based on biomarkers. Many companies are now targeting new markets such as the Asia Pacific region, where there is a high demand for targeted diagnostics, thus creating new opportunities for biomarker-driven solutions. Download PDF Brochure: Browse in-depth TOC on 'Biomarkers Market' 700 – Tables54 – Figures510 – Pages By offering, the biomarkers market is categorized into consumables, services, and software. Consumables are further sub segmented into assay kits, reagents & chemicals, and columns & filters. The consumables segment accounted for the largest share of the global biomarkers market in 2024. The large share of consumables is due to the high and recurring demand for assay kits, reagents, and other consumables in biomarker-based research, diagnostics, and validation workflows, which ensures continuous usage across laboratories and clinical settings. Additionally, the growing number of biomarker-based studies and clinical trials has driven the need for reliable, high-throughput consumables that support reproducibility and scalability. Moreover, the increasing adoption of multiplex assay platforms, which require specialized consumables to detect multiple biomarkers from limited sample volumes, also supports the large share of the consumables segment. By type, the biomarkers market is categorized into safety, efficacy, and validation biomarkers. The efficacy biomarkers are sub segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers. The safety biomarkers segment held the largest share in the biomarkers market in 2024. This can be attributed to the use of safety biomarkers in drug development to assess toxicity and identify potential adverse effects early in the development process. Regulatory agencies increasingly require safety biomarkers to ensure drug candidates meet safety standards before advancing to later stages of clinical trials. Additionally, pharmaceutical companies are investing in safety biomarker strategies to reduce the risk of late-stage failures and improve decision-making during preclinical and early clinical phases. By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based biomarkers, is estimated to register the highest CAGR during the forecast period of 2025-2030. This growth is supported by this technology's high sensitivity, cost-effectiveness, and broad applicability in detecting and quantifying genetic material. Companies can utilize this growth by expanding PCR-based test offerings, developing multiplex PCR kits, and integrating PCR platforms into biomarker-based diagnostics and companion tests. While PCR is expected to lead in growth, companies can also benefit from incorporating other technologies, such as NGS and MS, to support comprehensive biomarker analysis, particularly where high-throughput sequencing or protein-level insights are required. By geography, the biomarkers market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2024, North America held the largest share in the biomarkers market due to its well-established healthcare infrastructure, high research and development spending, and strong presence of leading pharmaceutical and biotechnology companies. The region has a high adoption rate of advanced technologies, including next-generation sequencing and companion diagnostics, which support biomarker discovery and application across clinical and research settings. Additionally, favorable regulatory frameworks, availability of funding from government and private sources, and a growing focus on precision medicine have further driven the use of biomarkers. The increasing burden of chronic diseases such as cancer and cardiovascular conditions has also contributed to sustained demand for biomarker-based diagnostics and therapies in the region. Request Sample Pages : Key players in the biomarkers market include F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), and JSR Corporation (Japan). The market includes many other prominent companies and competitive startups/SMEs. F. Hoffmann-La Roche Ltd (Switzerland): F. Hoffmann-La Roche Ltd is a major player in the global biomarker market, leveraging its integrated diagnostics-pharmaceutical business model, strong geographical presence, and ongoing innovation. The company operates in two segments: Diagnostics and Pharmaceuticals, with the Diagnostics division encompassing Core Lab, Molecular Lab, Pathology Lab, Point of Care, and Diabetes Care. These divisions provide biomarker-based assays, digital platforms, and companion diagnostics for applications in oncology, cardiology, neurology, infectious diseases, and diabetes. In 2023, Roche's Diagnostics division processed over 29 billion tests across more than 100,000 platforms, reflecting strong global demand. The company launched over 20 diagnostic assays between 2022 and May 2025, including the FDA-approved VENTANA MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer. Roche also actively pursues partnerships, such as collaborations with PathAI for AI-based pathology algorithms and with Neuron23 to utilize digital biomarkers in Parkinson's disease trials. Roche's integration of diagnostic development, test delivery, and data platforms, along with its global reach and AI-enabled R&D, enhances its leadership in the biomarker market. Merck KGaA (Germany) Merck KGaA is a major player in the biomarker market through its Life Science segment, which provides biomarker assays, consumables, software, and services for research and diagnostics. The Science & Lab Solutions division focuses on biomarker discovery, validation, and analysis. With a global presence and subsidiaries like EMD Millipore Corporation and Merck Biosciences AG, Merck has strengthened its position through strategic partnerships. In January 2025, it collaborated with Qpentions Labworks to automate assay workflows with the Flex robotic workstation, enhancing protein sample preparation. Additionally, in June 2024, Merck partnered with the Michael J. Fox Foundation to support the SMCXPRQ immunoassay platform for detecting low-abundance biomarkers related to early Parkinson's disease. This focus on automation and disease-specific advancements highlights Merck's significant role in the global biomarker market. For more information, Inquire Now! Related Reports: Cancer Biomarkers Market Cardiac Marker Testing Market Cancer Profiling Market Companion Diagnostics Market PCR Technologies Market Get access to the latest updates on Biomarkers Companies and Biomarkers Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: